机译:FDA批准摘要:Pembrolizumab用于治疗复发性或转移头和颈部鳞状细胞癌,含铂化疗的疾病进展
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
US FDA Ctr Drug Evaluat &
Res Off Hematol &
Oncol Prod WO22-2346 10903 New Hampshire Ave Silver;
Pembrolizumab; Squamous cell carcinoma of the head and neck; US Food and Drug Administration; Programmed cell death 1 receptor; Immunotherapy;
机译:FDA批准摘要:Pembrolizumab用于治疗复发性或转移头和颈部鳞状细胞癌,含铂化疗的疾病进展
机译:单独或用化疗与化疗与化学疗法进行复发性或转移性鳞状细胞癌(Keynote-048):随机开放标签,第3阶段研究(Vol 394,PG 1915,2019)
机译:单独或用化疗与化疗与化学疗法进行复发性或转移性鳞状细胞癌(Keynote-048):随机开放标签,第3阶段研究(Vol 394,PG 1915,2019)
机译:CCND1作为局部晚期头颈部鳞状细胞癌患者新辅助化疗的预测生物标志物
机译:趋化因子受体7在头颈部转移性鳞状细胞癌(SCCHN)中表达的炎症机制。
机译:FDA批准摘要:Pembrolizumab用于治疗复发或转移性头颈鳞状细胞癌并在含铂化疗后疾病进展